Latest News by Industry
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Apr 12, 2023--
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19, 2023, at 4:30 p.m. Eastern time.
A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx. A replay of the webcast will be available following the conclusion of the live broadcast.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.
DecisionDx-Melanoma, DecisionDx-CM Seq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UM Seq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.
View source version on businesswire.com:https://www.businesswire.com/news/home/20230412005085/en/
CONTACT: Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.comMedia Contact:
Allison Marshall
amarshall@castlebiosciences.com
KEYWORD: TEXAS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: ONCOLOGY MENTAL HEALTH HEALTH OTHER HEALTH PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Castle Biosciences, Inc.
Copyright Business Wire 2023.
PUB: 04/12/2023 07:00 AM/DISC: 04/12/2023 07:01 AM
http://www.businesswire.com/news/home/20230412005085/en